StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

ALX Oncology's total debt was $9.71M at Jun 30, 2026. For fiscal 2025 it was $9.75M, down 1.6% from the year before. The highest annual figure on record is $9.90M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.75M-1.6%
FY2024Dec 31, 2024$9.90M+2.7%
FY2023Dec 31, 2023$9.64M+2.7%
FY2022Dec 31, 2022$9.39M+73.2%
FY2019Dec 31, 2019$5.42M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.71M-3.3%
Q1 FY2026Mar 31, 2026$8.51M-14.6%
Q4 FY2025Dec 31, 2025$9.75M-1.6%
Q3 FY2025Sep 30, 2025$10.11M+2.8%
Q2 FY2025Jun 30, 2025$10.04M+2.8%
Q1 FY2025Mar 31, 2025$9.97M+2.8%
Q4 FY2024Dec 31, 2024$9.90M+2.7%
Q3 FY2024Sep 30, 2024$9.84M+2.7%
Q2 FY2024Jun 30, 2024$9.77M+2.7%
Q1 FY2024Mar 31, 2024$9.70M+2.7%
Q4 FY2023Dec 31, 2023$9.64M+2.7%
Q3 FY2023Sep 30, 2023$9.58M+66.2%
Q2 FY2023Jun 30, 2023$9.51M+68.6%
Q1 FY2023Mar 31, 2023$9.45M+74.3%
Q4 FY2022Dec 31, 2022$9.39M–
Q3 FY2020Sep 30, 2020$5.76M–
Q2 FY2020Jun 30, 2020$5.64M–
Q4 FY2019Dec 31, 2019$5.42M–

More ALX Oncology figures

See a number that looks wrong?